Literature DB >> 16908341

Azathioprine in dermatology: the past, the present, and the future.

Akash A Patel1, Robert A Swerlick, Calvin O McCall.   

Abstract

For several decades, dermatologists have utilized azathioprine to treat numerous debilitating skin diseases. This synthetic purine analog is derived from 6-mercaptopurine. It is thought to act by disrupting nucleic acid synthesis and has recently been found to interfere with T-cell activation. The most recognized uses of azathioprine in dermatology are for immunobullous diseases, generalized eczematous disorders, and photodermatoses. In this comprehensive review, the authors present recent advancements in the understanding of azathioprine and address aspects not covered in prior reviews. They (1) summarize the history of azathioprine; (2) discuss metabolism, integrating information from recent publications; (3) review the mechanism of action with attention paid to the activities of azathioprine not mediated by its 6-mercaptopurine metabolites and review new data about inhibition by azathioprine of the CD28 signal transduction pathway; (4) thoroughly examine thiopurine s-methyltransferase genetics, its clinical relevance, and interethnic variations; (5) review prior uses of azathioprine in the field of dermatology and grade the level of evidence; (6) discuss the use of azathioprine in pregnancy and pediatrics; review (7) key drug interactions and (8) adverse effects; (9) suggest a dosing and monitoring approach different from prior recommendations; and (10) explore the future of azathioprine, focusing on laboratory considerations and therapeutic application.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908341     DOI: 10.1016/j.jaad.2005.07.059

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  30 in total

1.  [Current status of oral immunomodulatory and immunosuppressive agents].

Authors:  S Meller; A M Baran; S A Braun; N Klossowski; B Homey
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

2.  Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.

Authors:  Katerina Wroblova; Michal Kolorz; Marian Batovsky; Vladimir Zboril; Jana Suchankova; Milan Bartos; Boris Ulicny; Igor Pav; Ladislava Bartosova
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

Review 3.  Combination therapies in multiple sclerosis.

Authors:  Ralf Gold
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

Review 4.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 5.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

6.  In vivo assessment of respiratory burst inhibition by xenobiotic exposure using larval zebrafish.

Authors:  Drake W Phelps; Ashley A Fletcher; Ivan Rodriguez-Nunez; Michele R Balik-Meisner; Debra A Tokarz; David M Reif; Dori R Germolec; Jeffrey A Yoder
Journal:  J Immunotoxicol       Date:  2020-12       Impact factor: 3.000

7.  Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring.

Authors:  Maura Caufield; Wynnis L Tom
Journal:  J Am Acad Dermatol       Date:  2012-08-11       Impact factor: 11.527

Review 8.  Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Authors:  Roxana Daneshjou; Rachel Huddart; Teri E Klein; Russ B Altman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

9.  Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain.

Authors:  David Gurwitz; Cristina Rodríguez-Antona; Katherine Payne; William Newman; Javier P Gisbert; Emma Gutiérrez de Mesa; Dolores Ibarreta
Journal:  Eur J Hum Genet       Date:  2009-02-18       Impact factor: 4.246

Review 10.  Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.